The National Institute for Health and Clinical Excellence (NICE) has issued a Technology Appraisal for the use of pemetrexed for the treatment of malignant pleural mesothelioma, and makes the following recommendations (taken directly from source):
• Pemetrexed is recommended as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organisation (WHO) performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate
• Patients currently receiving pemetrexed who do not fall into the patient population defined above should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
Saturday
Treatment of Malignant Pleural Mesothelioma
